drugset / Trial / NCT06829173
Concurrent XRD-0394 With Radiation Therapy for High Grade Gliomas
RandomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, dose-finding study of XRD-0394 in subjects with newly diagnosed and recurrent high grade gliomas receiving radiation therapy, with and without concurrent temozolomide based on O6-Methylguanine-DNA methyltransferase (MGMT) status for patients with newly diagnosed high grade gliomas.
Timeline
- Start
- 2025-11-05
- Primary completion
- 2027-05
- Completion
- 2031-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | XRD-0394 | Small molecule | 160 mg | Oral |
| Subject | XRD-0394 | Small molecule | 300 mg | Oral |